Mazdutide (IBI362) is a novel dual agonist peptide targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors, developed to explore synergistic metabolic pathways in preclinical and clinical research settings. By simultaneously activating GLP-1 receptors — which promote insulin secretion, reduce glucagon release, and suppress appetite — alongside glucagon receptors that stimulate hepatic glucose output and energy expenditure, mazdutide presents a compelling dual mechanism with implications for bodyweight regulation, glycaemic control, and lipid metabolism research.
In research contexts, mazdutide has been investigated for its potential to reduce body weight, improve insulin sensitivity, and modulate hepatic fat accumulation, making it a subject of considerable interest in type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and obesity studies. Early-phase clinical trial data have demonstrated meaningful reductions in HbA1c and body mass index (BMI) in relevant populations.
Store at −20°C. Protect from light and moisture. Reconstitute using bacteriostatic water or sterile saline.
Molecular Formula
C₁₅₈H₂₅₁N₄₃O₄₉
Molecular Weight
3613.9 g/mol
Purity
>98%
CAS Number
2413354-86-4
Form
Lyophilised Powder
Research Applications
Obesity and body weight regulation, Type 2 diabetes and glycaemic control, Non-alcoholic fatty liver disease (NAFLD), Lipid metabolism, Insulin sensitivity, Energy expenditure modulation
For research purposes only. Not for human use.
Reviews
There are no reviews yet.